Great Ormond Street Hospital for Children NHS Foundation Trust
London, WC1N 1EH, United Kingdom
NCT Number: NCT02199340
The progression of lung disease in cystic fibrosis (CF) results inevitably in a reduction in exercise capacity. The assessment of fitness and exercise capacity in CF is an important measure of the impact of the disease process, particularly if it is repeated over time. With recent advances in clinical management, CF lung disease in children can be relatively mild and exercise tolerance good. The currently available field tests e.g. 3 minute step test, are often completed too easily. These tests provide limited information relating to maximal exercise performance. By contrast, the maximal CardioPulmonary Exercise Test (CPET), a progressive, incremental, gold standard exercise test with breath by breath analysis of expired gas, has proved to be a valuable means of assessing exercise response in patients with CF. Its only limitation is the requirement for specialist laboratory facilities, equipment and staff.
A new field test for evaluating exercise capacity in children is needed. This should be portable, easy to administer and simple to perform by young children, while providing a higher intensity of exercise which correlates with day to day activity patterns of children, and clinically relevant information in the short term and longitudinally. This test needs to be a good surrogate measure of exercise capacity when formal CPET is unable to be undertaken. By providing accurate and useful information the results can be used to prescribe and train individuals with CF safely and effectively and can also be used in the short and long term for guidance of the medical management of these complex patients.
The aim of this study is to develop and validate the use of a new incremental step test to assess exercise tolerance/capacity in children with CF, compare this with the gold standard CPET and to provide normative healthy control comparison data The main objectives of the study are
1. To develop an incremental step test to assess exercise tolerance / capacity in children with CF. 2. To compare the incremental step test with the gold standard CPET 3. To assess the level of exercise response produced by the incremental step test 4. To assess the correlation between independent variables of lung function measurements, age, weight and height with VO2peak and other exercise test outcomes 5. To assess the repeatability and evaluate the normal variability of the new incremental step test 6. To provide healthy control normative data for comparison
Looking for future studies?
Notify Me6 year–16 year
All sexes
Interventional
Not applicable
London, WC1N 1EH, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Clinical population inclusion
Healthy control population inclusion
Exclusion criteria
Clinical population exclusion
Healthy control population exclusion
newly developed submaximal exercise test
maximal gold standard exercise test
Time frame: Measured during the exercise test, day 1, maximum of 20 minutes
Gold standard exercise test to determine peak oxygen uptake during exercise
Time frame: Measured during the exercise test, day 1, maximum of 20 minutes
Time frame: Measured during the exercise test, day 1, maximum of 20 minutes
Standard field exercise test outcomes of heart rate, oxygen saturations, time, level achieved, rate of perceived exertion, perceived breathlessness
Time frame: Measured at baseline on the day of testing, day 1, maximum of 5 minutes
Height, weight and body mass index will be measured for descriptive purposes only
Time frame: Measured at the end of the exercise test, day 1, maximum of 5 minutes
Great Ormond Street Hospital for Children NHS Foundation Trust
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02715921
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Irvine, California, United States
View Trial DetailsNCT04798014
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Indianapolis, Indiana, United States
View Trial DetailsNCT03938324
Anemia, Anemia, Hemolytic
Durham, North Carolina, United States
View Trial DetailsNCT05453578
Bacterial Disease Carrier, Bacterial Infections
Tucson, Arizona, United States
View Trial Details